Retatrutide (LY3437943): The Triple Agonist Peptide — Mechanism, Trial Data & Research Overview

What is Retatrutide?

Retatrutide — INN name retatrutide, development code LY3437943 — is an investigational peptide developed by Eli Lilly and Company. It is a 39-amino-acid synthetic peptide with a fatty acid conjugation that dramatically extends its circulating half-life to approximately 6 days, enabling once-weekly subcutaneous dosing [1].

What sets retatrutide apart from every other metabolic peptide currently in clinical development is its triple receptor activity. While semaglutide (Ozempic/Wegovy) targets only the GLP-1 receptor, and tirzepatide (Mounjaro) targets GLP-1 and GIP receptors, retatrutide adds a third dimension: glucagon receptor (GcgR) agonism. This makes it the world's first triple GLP-1/GIP/glucagon agonist to advance through controlled clinical trials [1].

Retatrutide entered Phase II trials in 2021 (NCT04881760) and published landmark results in the New England Journal of Medicine in 2023, demonstrating 24.2% body weight reduction at 48 weeks in the highest dose group [1]. Phase III trials (SURMOUNT programme) were initiated in 2023. As of 2024, retatrutide remains an investigational compound and is not approved for clinical use anywhere in the world.

How it works: triple agonist mechanism

Retatrutide's pharmacological profile is the product of three simultaneous receptor engagements, each contributing a distinct metabolic action. The interplay of these three axes creates an effect that is qualitatively different from GLP-1 monotherapy or dual GLP-1/GIP agonism.

GLP-1 receptor agonism

GLP-1 (glucagon-like peptide-1) receptor agonism is the foundational mechanism shared with semaglutide and tirzepatide. GLP-1R activation delays gastric emptying, increases satiety signalling in the hypothalamus, stimulates insulin secretion in a glucose-dependent manner, and suppresses glucagon release from pancreatic alpha cells. The net result is reduced caloric intake, improved post-meal glucose control, and slower gut transit that prolongs the sensation of fullness [1].

GIP receptor agonism

GIP (glucose-dependent insulinotropic polypeptide) receptor agonism works synergistically with GLP-1R activation to amplify insulin secretion. GIPR agonism also improves lipid metabolism and, critically, has been shown in preclinical models to attenuate the GI side effects (nausea, vomiting) that typically limit GLP-1 agonist tolerability [3]. This is why tirzepatide — and now retatrutide — tend to produce less nausea relative to the weight loss they achieve compared to GLP-1 monotherapy at equivalent weight-reduction doses.

Glucagon receptor agonism — the differentiating factor

The glucagon receptor component is what fundamentally distinguishes retatrutide from all other approved or late-stage metabolic peptides. Glucagon receptor agonism increases energy expenditure through thermogenesis, promotes lipolysis in adipose tissue, and drives hepatic glucose output. In isolation, glucagon would be problematic — it raises blood glucose — but when balanced by simultaneous GLP-1R and GIPR activation (which both suppress glucagon and stimulate insulin), the hyperglycaemic effect is neutralised while the energy-expenditure and fat-burning effects are preserved [1].

This "metabolic triple attack" — reduced appetite (GLP-1) + enhanced insulin response (GLP-1 + GIP) + increased energy expenditure and lipolysis (GcgR) — explains why retatrutide produces substantially greater weight loss than dual agonists at comparable doses. The glucagon axis adds a thermogenic, fat-burning dimension that no other approved or trial-stage weight-loss drug currently provides.

Documented research benefits

The following benefits are drawn from the Phase II NEJM trial (Jastreboff et al. 2023) and supporting literature. Retatrutide has not completed Phase III trials; all data are from controlled research settings and do not constitute a therapeutic claims framework.

Unprecedented weight loss in Phase II trial

The Jastreboff et al. 2023 Phase II trial enrolled 338 adults with obesity (BMI ≥ 30) or overweight with comorbidities and randomised them to weekly subcutaneous retatrutide at doses of 1 mg, 4 mg, 8 mg, or 12 mg, or placebo, for 48 weeks. The 12 mg dose group achieved 17.5% body weight reduction at 24 weeks and 24.2% at 48 weeks — the highest weight loss outcome ever reported in a clinical trial of any pharmacological agent at the time of publication [1]. For context, semaglutide 2.4 mg (Wegovy) achieved approximately 15% at 68 weeks in STEP-1; tirzepatide 15 mg achieved approximately 21% at 72 weeks in SURMOUNT-1.

Glycaemic control

In the Phase II trial, participants with elevated baseline HbA1c showed significant reductions across all retatrutide dose groups. The dual insulin-stimulating effect (GLP-1 + GIP) delivered glucose lowering that exceeded what would be expected from weight loss alone, consistent with direct beta-cell activity. This positions retatrutide as a potential treatment for both obesity and type 2 diabetes in a single compound [1].

Lipid profile improvements

Secondary endpoints in the Phase II trial showed meaningful reductions in triglycerides and LDL cholesterol, and increases in HDL cholesterol. These lipid changes — driven in part by the GcgR-mediated lipolysis and the weight loss itself — represent a cardiovascular risk-reduction profile that mirrors what has been observed with semaglutide and tirzepatide, but potentially more pronounced given the greater magnitude of fat mass reduction [1].

Non-alcoholic fatty liver disease (NAFLD)

Hepatic fat fraction was assessed as a secondary endpoint in the Phase II trial. Retatrutide produced significant reductions in liver fat content, consistent with the known hepatic effects of glucagon receptor agonism (which directly drives hepatic lipid oxidation) combined with the weight loss-driven reduction in metabolic liver disease burden. NAFLD is a major unmet medical need with no approved pharmacotherapy, and retatrutide's data here are among the most compelling in the pipeline [1].

Dosing ranges in published literature

The Phase II trial used a structured dose-escalation protocol to minimise GI side effects — a critical design feature of GLP-1 class peptides. Participants were titrated upward from a starting dose of 0.5 mg over 16 weeks before reaching their maintenance dose. The escalation schedule from the trial is summarised below [1].

The most effective dose in the Phase II trial was 12 mg/week SC, achieving 24.2% body weight reduction at 48 weeks. The 8 mg dose achieved approximately 22.8% at 48 weeks. Both are substantially higher than any currently approved pharmacotherapy for obesity [1]. These are Phase III trial doses, not recommendations.

Administration & reconstitution

Route of administration

Retatrutide is administered exclusively by subcutaneous injection, once weekly. The extended half-life (~6 days) conferred by its fatty acid conjugation is specifically designed for weekly dosing intervals — daily or more frequent administration is neither necessary nor tested [1].

In the clinical trials, retatrutide was supplied as a pre-filled syringe for injection. Research-grade material is supplied as lyophilised powder requiring reconstitution before use.

Reconstitution protocol (lyophilised powder)

Standard bacteriostatic water (0.9% benzyl alcohol in sterile water for injection) is used for reconstitution. Retatrutide's 39-amino-acid length and fatty acid conjugation mean it is somewhat less soluble than shorter peptides; use a gentle swirling action rather than shaking.

1. Allow vial to reach room temperature before opening
2. Add bacteriostatic water slowly down the inside wall of the vial — do not inject directly onto the powder cake
3. Gently swirl in a circular motion; do not vortex or shake vigorously
4. Allow 2–3 minutes for full dissolution; the solution should be clear
5. Store reconstituted solution at 2–8°C, protected from light
6. Use within 28 days of reconstitution

Titration note

Slow dose escalation is essential with retatrutide, as with all GLP-1 class peptides. The Phase II trial used a 16-week escalation to maintenance dose specifically to minimise GI adverse events. Rushing the titration markedly increases nausea and vomiting risk without adding efficacy benefit.

Side effects and safety data

Retatrutide's Phase II safety data are the most robust available for this compound. The following profile reflects the Jastreboff et al. 2023 trial across all dose groups [1].

Most common adverse events (Phase II)

• Nausea — reported in ~40% of participants; most common during escalation; generally resolved at maintenance dose
• Vomiting — approximately 21%; again most pronounced during titration
• Diarrhoea — approximately 13%
• Constipation — less common; occurs as gastric emptying slows
• Injection site reactions — mild, localised; consistent with SC administration of any peptide
• Heart rate increase — a class effect of GLP-1 agonists; modest pulse rate elevations observed across dose groups, consistent with semaglutide and tirzepatide data

Theoretical class-effect risks

• Gallbladder events — rapid weight loss is associated with gallstone formation; this is a class effect of GLP-1 agonists and was monitored in Phase II
• Pancreatitis — a rare but documented class effect of GLP-1 agonists; no excess signal was observed in Phase II, but Phase III surveillance is ongoing
• Thyroid C-cell concerns — a regulatory precaution carried by the GLP-1 class based on rodent data; clinical significance in humans remains uncharacterised

Important: Retatrutide is not approved in any jurisdiction. All safety data are from Phase II trials; the full safety profile will not be known until Phase III completion. Long-term effects are unknown.

Interactions & contraindications

No formal drug-drug interaction studies have been published for retatrutide specifically. The following considerations are based on its mechanisms and the established pharmacology of the GLP-1/GIP class:

• Other GLP-1 or GIP agonists (semaglutide, tirzepatide, liraglutide) — do not combine. Overlapping mechanisms create risk of excessive GI toxicity, hypoglycaemia, and unpredictable receptor saturation. There is no studied safe combination dose.
• Insulin and sulfonylureas — retatrutide's insulin-stimulating mechanisms combined with exogenous insulin or insulin secretagogues substantially increase hypoglycaemia risk; dose adjustment of the insulin/sulfonylurea would be required under physician supervision
• Oral medications — delayed gastric emptying (a GLP-1 class effect) slows the absorption of orally administered drugs; this is clinically relevant for narrow-therapeutic-index medications (e.g., warfarin, cyclosporin, certain antibiotics) where absorption timing affects efficacy or safety
• Glucocorticoids — corticosteroids drive insulin resistance and weight gain, which may oppose retatrutide's effects; no interaction data exist

Storage & stability

As a fatty acid-conjugated 39-amino-acid peptide, retatrutide is less thermostable than shorter, unconjugated peptides. Proper cold-chain storage is important for maintaining potency, particularly after reconstitution.

Frequently asked questions

How does retatrutide compare to semaglutide (Ozempic/Wegovy)?

Semaglutide is a GLP-1 receptor agonist only. Retatrutide adds GIP and glucagon receptor agonism on top of GLP-1R activity. In direct trial comparison (noting these are different trials, not head-to-head), semaglutide 2.4 mg achieved ~15% body weight reduction at 68 weeks (STEP-1), while retatrutide 12 mg achieved 24.2% at 48 weeks — a shorter timeframe for substantially more weight loss. The glucagon component, which drives thermogenesis and lipolysis, is the primary differentiator.

What makes the glucagon receptor component different?

Glucagon is typically thought of as a hyperglycaemic hormone — it raises blood glucose by stimulating hepatic glucose output. In retatrutide, the co-activation of GLP-1R and GIPR simultaneously stimulates insulin release, which offsets the glucagon-driven glucose elevation. What remains is the anabolic-opposing effect of glucagon: increased energy expenditure, thermogenesis, and fat mobilisation from adipose tissue. This is a thermogenic mechanism that no approved weight-loss drug currently activates.

Is retatrutide approved?

No. As of 2024, retatrutide is in Phase III clinical trials. It is not approved by the FDA, EMA, CDSCO (India), or any other regulatory body. It is an investigational compound available only in the context of clinical trials or as a research compound for laboratory use.

What weight loss did Phase II trials show?

The Jastreboff et al. 2023 Phase II NEJM trial reported 17.5% body weight reduction at 24 weeks and 24.2% at 48 weeks in the 12 mg weekly dose group. This was the highest weight loss outcome reported in any pharmacological trial at the time of publication [1].

Is retatrutide available in India?

Retatrutide is not approved as a pharmaceutical in India and is not available through licensed pharmacy channels. It is available as a research compound for laboratory use through verified research peptide suppliers. PEPTIGRID carries retatrutide from three GMP-certified manufacturers — Gold Bond Labs, Denik Pharm, and Enhanced Pharma. See our Gold Bond Labs, Denik Pharm, and Enhanced Pharma product pages for current availability and pricing.